nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—Splenomegaly—Propylthiouracil—Graves' disease	0.0622	0.0949	CcSEcCtD
Lenalidomide—TNFSF11—connective tissue—Graves' disease	0.0599	0.201	CbGeAlD
Lenalidomide—CDH5—connective tissue—Graves' disease	0.045	0.151	CbGeAlD
Lenalidomide—Lung infiltration—Propylthiouracil—Graves' disease	0.0368	0.0562	CcSEcCtD
Lenalidomide—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.0357	0.0545	CcSEcCtD
Lenalidomide—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0352	0.0537	CcSEcCtD
Lenalidomide—CDH5—pituitary gland—Graves' disease	0.0347	0.117	CbGeAlD
Lenalidomide—CDH5—adipose tissue—Graves' disease	0.0346	0.116	CbGeAlD
Lenalidomide—CDH5—thyroid gland—Graves' disease	0.0299	0.101	CbGeAlD
Lenalidomide—Pomalidomide—TNF—Graves' disease	0.0287	0.608	CrCbGaD
Lenalidomide—Neuritis—Methimazole—Graves' disease	0.0272	0.0415	CcSEcCtD
Lenalidomide—Ageusia—Methimazole—Graves' disease	0.0251	0.0382	CcSEcCtD
Lenalidomide—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0244	0.0372	CcSEcCtD
Lenalidomide—Neuritis—Propylthiouracil—Graves' disease	0.0231	0.0353	CcSEcCtD
Lenalidomide—CRBN—pituitary gland—Graves' disease	0.022	0.0741	CbGeAlD
Lenalidomide—CRBN—adipose tissue—Graves' disease	0.022	0.0738	CbGeAlD
Lenalidomide—Ageusia—Propylthiouracil—Graves' disease	0.0213	0.0325	CcSEcCtD
Lenalidomide—CRBN—thyroid gland—Graves' disease	0.019	0.0639	CbGeAlD
Lenalidomide—Thalidomide—TNF—Graves' disease	0.0185	0.392	CrCbGaD
Lenalidomide—Lymphadenopathy—Methimazole—Graves' disease	0.0173	0.0264	CcSEcCtD
Lenalidomide—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0147	0.0224	CcSEcCtD
Lenalidomide—Hepatic failure—Propylthiouracil—Graves' disease	0.0139	0.0213	CcSEcCtD
Lenalidomide—Renal failure acute—Propylthiouracil—Graves' disease	0.0136	0.0207	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Methimazole—Graves' disease	0.0111	0.017	CcSEcCtD
Lenalidomide—Agranulocytosis—Methimazole—Graves' disease	0.0106	0.0162	CcSEcCtD
Lenalidomide—Hepatitis—Methimazole—Graves' disease	0.0102	0.0156	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00946	0.0144	CcSEcCtD
Lenalidomide—Agranulocytosis—Propylthiouracil—Graves' disease	0.00901	0.0138	CcSEcCtD
Lenalidomide—Alopecia—Methimazole—Graves' disease	0.00901	0.0137	CcSEcCtD
Lenalidomide—Haemoglobin—Propylthiouracil—Graves' disease	0.00871	0.0133	CcSEcCtD
Lenalidomide—Hepatitis—Propylthiouracil—Graves' disease	0.00867	0.0132	CcSEcCtD
Lenalidomide—Haemorrhage—Propylthiouracil—Graves' disease	0.00867	0.0132	CcSEcCtD
Lenalidomide—Vertigo—Methimazole—Graves' disease	0.00797	0.0122	CcSEcCtD
Lenalidomide—Leukopenia—Methimazole—Graves' disease	0.00794	0.0121	CcSEcCtD
Lenalidomide—PTGS2—connective tissue—Graves' disease	0.00779	0.0262	CbGeAlD
Lenalidomide—Alopecia—Propylthiouracil—Graves' disease	0.00766	0.0117	CcSEcCtD
Lenalidomide—Arthralgia—Methimazole—Graves' disease	0.00755	0.0115	CcSEcCtD
Lenalidomide—Myalgia—Methimazole—Graves' disease	0.00755	0.0115	CcSEcCtD
Lenalidomide—Dysgeusia—Propylthiouracil—Graves' disease	0.00739	0.0113	CcSEcCtD
Lenalidomide—Oedema—Methimazole—Graves' disease	0.00724	0.0111	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methimazole—Graves' disease	0.00709	0.0108	CcSEcCtD
Lenalidomide—Vertigo—Propylthiouracil—Graves' disease	0.00678	0.0103	CcSEcCtD
Lenalidomide—Leukopenia—Propylthiouracil—Graves' disease	0.00675	0.0103	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methimazole—Graves' disease	0.0066	0.0101	CcSEcCtD
Lenalidomide—Paraesthesia—Methimazole—Graves' disease	0.0065	0.00992	CcSEcCtD
Lenalidomide—Somnolence—Methimazole—Graves' disease	0.00644	0.00983	CcSEcCtD
Lenalidomide—Arthralgia—Propylthiouracil—Graves' disease	0.00642	0.0098	CcSEcCtD
Lenalidomide—Myalgia—Propylthiouracil—Graves' disease	0.00642	0.0098	CcSEcCtD
Lenalidomide—Dyspepsia—Methimazole—Graves' disease	0.00638	0.00973	CcSEcCtD
Lenalidomide—Oedema—Propylthiouracil—Graves' disease	0.00616	0.0094	CcSEcCtD
Lenalidomide—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00603	0.0092	CcSEcCtD
Lenalidomide—PTGS2—pituitary gland—Graves' disease	0.006	0.0202	CbGeAlD
Lenalidomide—PTGS2—adipose tissue—Graves' disease	0.00598	0.0201	CbGeAlD
Lenalidomide—Urticaria—Methimazole—Graves' disease	0.00575	0.00878	CcSEcCtD
Lenalidomide—Body temperature increased—Methimazole—Graves' disease	0.00573	0.00874	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00561	0.00856	CcSEcCtD
Lenalidomide—Paraesthesia—Propylthiouracil—Graves' disease	0.00553	0.00844	CcSEcCtD
Lenalidomide—Somnolence—Propylthiouracil—Graves' disease	0.00547	0.00835	CcSEcCtD
Lenalidomide—Dyspepsia—Propylthiouracil—Graves' disease	0.00542	0.00827	CcSEcCtD
Lenalidomide—Pruritus—Methimazole—Graves' disease	0.00512	0.00782	CcSEcCtD
Lenalidomide—Urticaria—Propylthiouracil—Graves' disease	0.00489	0.00747	CcSEcCtD
Lenalidomide—Body temperature increased—Propylthiouracil—Graves' disease	0.00487	0.00743	CcSEcCtD
Lenalidomide—Vomiting—Methimazole—Graves' disease	0.0046	0.00703	CcSEcCtD
Lenalidomide—Rash—Methimazole—Graves' disease	0.00457	0.00697	CcSEcCtD
Lenalidomide—Dermatitis—Methimazole—Graves' disease	0.00456	0.00696	CcSEcCtD
Lenalidomide—Headache—Methimazole—Graves' disease	0.00454	0.00692	CcSEcCtD
Lenalidomide—Pruritus—Propylthiouracil—Graves' disease	0.00436	0.00665	CcSEcCtD
Lenalidomide—Nausea—Methimazole—Graves' disease	0.0043	0.00656	CcSEcCtD
Lenalidomide—Vomiting—Propylthiouracil—Graves' disease	0.00392	0.00598	CcSEcCtD
Lenalidomide—Rash—Propylthiouracil—Graves' disease	0.00388	0.00593	CcSEcCtD
Lenalidomide—Dermatitis—Propylthiouracil—Graves' disease	0.00388	0.00592	CcSEcCtD
Lenalidomide—Headache—Propylthiouracil—Graves' disease	0.00386	0.00589	CcSEcCtD
Lenalidomide—ABCB1—pituitary gland—Graves' disease	0.00371	0.0125	CbGeAlD
Lenalidomide—ABCB1—adipose tissue—Graves' disease	0.0037	0.0124	CbGeAlD
Lenalidomide—Nausea—Propylthiouracil—Graves' disease	0.00366	0.00558	CcSEcCtD
Lenalidomide—ABCB1—thyroid gland—Graves' disease	0.0032	0.0108	CbGeAlD
